{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:22:05Z","timestamp":1784236925163,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health Commission of Gansu Prevince","award":["No.2025-086"],"award-info":[{"award-number":["No.2025-086"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetic macular edema (DME) is one of the leading causes of blindness in diabetic retinopathy. As a domestically developed fusion protein drug in China, the anti-vascular endothelial growth factor (VEGF) agent Conbercept has demonstrated significant efficacy in the treatment of DME in recent years. This systematic review explores the mechanism of action and latest research advancements of Conbercept in DME treatment, integrating clinical trial data and comparisons with other anti-VEGF therapies. It further discusses existing limitations in current research and proposes future research directions.<\/jats:p>","DOI":"10.1186\/s40942-025-00738-6","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:32:57Z","timestamp":1760621577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances in the study of Conbercept for diabetic macular edema"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3249-9164","authenticated-orcid":false,"given":"Zhe","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-4127","authenticated-orcid":false,"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1688-9268","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"738_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 11th edn. Brussels, Belgium: International Diabetes Federation, 2025."},{"key":"738_CR2","doi-asserted-by":"publisher","first-page":"1128811","DOI":"10.3389\/fmed.2023.1128811","volume":"10","author":"CD Haydinger","year":"2023","unstructured":"Haydinger CD, Ferreira LB, Williams KA, Smith JR. Mechanisms of macular edema. Front Med (Lausanne). 2023;10:1128811. Published 2023 Mar 7. https:\/\/doi.org\/10.3389\/fmed.2023.1128811.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"738_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","volume":"68","author":"OA Sorour","year":"2023","unstructured":"Sorour OA, Levine ES, Baumal CR, et al. Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023;68(2):147\u201374. https:\/\/doi.org\/10.1016\/j.survophthal.2022.11.008.","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"738_CR4","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","volume":"38","author":"M Weiss","year":"2018","unstructured":"Weiss M, Sim DA, Herold T, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2018;38(12):2293\u2013300. https:\/\/doi.org\/10.1097\/IAE.0000000000001892.","journal-title":"Retina"},{"issue":"5","key":"738_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/APO.0000000000000312","volume":"9","author":"J Chhablani","year":"2020","unstructured":"Chhablani J, Wong K, Tan GS, et al. Diabetic macular edema management in Asian population: expert panel consensus guidelines. Asia Pac J Ophthalmol (Phila). 2020;9(5):426\u201334. https:\/\/doi.org\/10.1097\/APO.0000000000000312.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"738_CR6","doi-asserted-by":"publisher","unstructured":"Zhang J, Zhang J, Zhang C et al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022;11(21):3362. Published 2022 Oct 25. https:\/\/doi.org\/10.3390\/cells11213362.","DOI":"10.3390\/cells11213362"},{"issue":"6","key":"738_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.survophthal.2024.07.006","volume":"69","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic S, Lupidi M, Donati S, Astarita C, Gallinaro V, Pilotto E. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration. Surv Ophthalmol. 2024;69(6):870\u201381. https:\/\/doi.org\/10.1016\/j.survophthal.2024.07.006.","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"738_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4103\/1673-5374.355743","volume":"18","author":"L Tang","year":"2023","unstructured":"Tang L, Xu GT, Zhang JF. Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res. 2023;18(5):976\u201382. https:\/\/doi.org\/10.4103\/1673-5374.355743.","journal-title":"Neural Regen Res"},{"key":"738_CR9","doi-asserted-by":"publisher","first-page":"105115","DOI":"10.1016\/j.phrs.2020.105115","volume":"161","author":"M Rudraraju","year":"2020","unstructured":"Rudraraju M, Narayanan SP, Somanath PR. Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy. Pharmacol Res. 2020;161:105115. https:\/\/doi.org\/10.1016\/j.phrs.2020.105115.","journal-title":"Pharmacol Res"},{"issue":"08","key":"738_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3760\/cma.j.cn511434-20220620-00371","volume":"39","author":"WJ Yan","year":"2023","unstructured":"Yan WJ, Luo DL, Feng JJ, Ding XY. An update on anti-vascular endothelial growth factor therapy in retinal diseases. Chin J Ocular Fundus Dis. 2023;39(08):701\u20137. https:\/\/doi.org\/10.3760\/cma.j.cn511434-20220620-00371.","journal-title":"Chin J Ocular Fundus Dis"},{"key":"738_CR11","doi-asserted-by":"publisher","unstructured":"Liu QQ, Gao HL, Li XM, Yu R, Zhang L. Application of anti-vascular endothelial growth factor fusion protein in ophthalmology. Int Rev Ophthalmol 2020,44(02):126\u201332. https:\/\/doi.org\/10.3760\/cma.j.issn.1673-5803.2020.02.010.","DOI":"10.3760\/cma.j.issn.1673-5803.2020.02.010"},{"issue":"1","key":"738_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","volume":"97","author":"H Li","year":"2012","unstructured":"Li H, Lei N, Zhang M, Li Y, Xiao H, Hao X. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res. 2012;97(1):154\u20139. https:\/\/doi.org\/10.1016\/j.exer.2011.09.002.","journal-title":"Exp Eye Res"},{"issue":"1","key":"738_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41598-017-00683-x","volume":"7","author":"J Wang","year":"2017","unstructured":"Wang J, Lei C, Tao L, et al. A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits. Sci Rep. 2017;7(1):592. Published 2017 Apr 4. https:\/\/doi.org\/10.1038\/s41598-017-00683-x.","journal-title":"Sci Rep"},{"key":"738_CR14","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.2147\/DDDT.S176021","volume":"12","author":"L Wang","year":"2018","unstructured":"Wang L, Zhang C, Hua R. Clinical effectiveness of Ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis. Drug Des Devel Ther. 2018;12:3625\u201333. Published 2018 Oct 29. https:\/\/doi.org\/10.2147\/DDDT.S176021.","journal-title":"Drug Des Devel Ther"},{"key":"738_CR15","first-page":"636","volume":"25","author":"Q Zhou","year":"2019","unstructured":"Zhou Q, Guo C, You A, Wang D, Wang W, Zhang X. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema. Mol Vis. 2019;25:636\u201344. Published 2019 Oct 21.","journal-title":"Mol Vis"},{"key":"738_CR16","doi-asserted-by":"publisher","first-page":"118795","DOI":"10.1016\/j.lfs.2020.118795","volume":"265","author":"JP Xia","year":"2021","unstructured":"Xia JP, Liu SQ, Wang S. Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress. Life Sci. 2021;265:118795. https:\/\/doi.org\/10.1016\/j.lfs.2020.118795.","journal-title":"Life Sci"},{"issue":"12","key":"738_CR17","doi-asserted-by":"publisher","first-page":"e24774","DOI":"10.1002\/jcla.24774","volume":"36","author":"Y Huang","year":"2022","unstructured":"Huang Y, Linghu M, Hu W, Huang X. Conbercept improves macular microcirculation and retinal blood supply in the treatment of nonischemic branch retinal vein occlusion macular edema. J Clin Lab Anal. 2022;36(12):e24774. https:\/\/doi.org\/10.1002\/jcla.24774.","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"738_CR18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.18240\/ijo.2025.07.07","volume":"18","author":"YY Zhu","year":"2025","unstructured":"Zhu YY, Qin SY, Xie H, et al. Enhancement of retinal M\u00fcller glia\u2019s phagocytic activity against hard exudates by conbercept via activation of PPAR\u03b3-CD36 axis in diabetic retinopathy. Int J Ophthalmol. 2025;18(7):1252\u201361. Published 2025 Jul 18. https:\/\/doi.org\/10.18240\/ijo.2025.07.07.","journal-title":"Int J Ophthalmol"},{"issue":"10","key":"738_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/bjophthalmol-2020-318690","volume":"106","author":"K Liu","year":"2022","unstructured":"Liu K, Wang H, He W, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. 2022;106(10):1436\u201343. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318690.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"738_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.18240\/ijo.2021.03.14","volume":"14","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Yuan L, Zhao MW, Qian T. Real-world outcomes of two-year conbercept therapy for diabetic macular edema. Int J Ophthalmol. 2021;14(3):416\u201322. Published 2021 Mar 18. https:\/\/doi.org\/10.18240\/ijo.2021.03.14.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"738_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12886-019-1131-0","volume":"19","author":"Y Xu","year":"2019","unstructured":"Xu Y, Qu Y, Suo Y, et al. Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment. BMC Ophthalmol. 2019;19(1):123. Published 2019 May 31. https:\/\/doi.org\/10.1186\/s12886-019-1131-0.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"738_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.18240\/ijo.2024.02.12","volume":"17","author":"YZ Zhu","year":"2024","unstructured":"Zhu YZ, Dou ZZ, Wang WY, et al. Intravitreal injection of conbercept for diabetic macular edema complicated with diabetic nephropathy. Int J Ophthalmol. 2024;17(2):304\u201310. Published 2024 Feb 18. https:\/\/doi.org\/10.18240\/ijo.2024.02.12.","journal-title":"Int J Ophthalmol"},{"issue":"8","key":"738_CR23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00592-020-01511-x","volume":"57","author":"Y Di","year":"2020","unstructured":"Di Y, Li Z, Ye J, Li L, Li B, Yu R. The fellow eye effect of unilateral intravitreal conbercept injections in eyes with diabetic macular edema. Acta Diabetol. 2020;57(8):1001\u20137. https:\/\/doi.org\/10.1007\/s00592-020-01511-x.","journal-title":"Acta Diabetol"},{"issue":"6","key":"738_CR24","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.18240\/ijo.2024.06.1140","volume":"17","author":"Y Xu","year":"2024","unstructured":"Xu Y, Ye Q, Shen W. Intravitreal conbercept injection with panretinal photocoagulation for high-risk proliferative diabetic retinopathy with vitreous hemorrhage. Int J Ophthalmol. 2024;17(6):1066\u201372. Published 2024 Jun 18. https:\/\/doi.org\/10.18240\/ijo.2024.06.1140.","journal-title":"Int J Ophthalmol"},{"key":"738_CR25","doi-asserted-by":"publisher","first-page":"103745","DOI":"10.1016\/j.pdpdt.2023.103745","volume":"44","author":"F Ren","year":"2023","unstructured":"Ren F, Zhang X, Gong H, et al. Two different initial treatment regimens of conbercept in diabetic macular edema: 12-month results from a multicenter randomized controlled study. Photodiagnosis Photodyn Ther. 2023;44:103745. https:\/\/doi.org\/10.1016\/j.pdpdt.2023.103745.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"7","key":"738_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.13.7.4","volume":"13","author":"J Baek","year":"2024","unstructured":"Baek J, He Y, Emamverdi M, et al. Prediction of Long-Term treatment outcomes for diabetic macular edema using a generative adversarial network. Transl Vis Sci Technol. 2024;13(7):4. https:\/\/doi.org\/10.1167\/tvst.13.7.4.","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"738_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10792-025-03646-8","volume":"45","author":"X Zhao","year":"2025","unstructured":"Zhao X, Lin Z, Long T, Yang G, Zhang J. Early combined conbercept and dexamethasone implant therapy for diabetic macular edema. Int Ophthalmol. 2025;45(1):267. Published 2025 Jun 27. https:\/\/doi.org\/10.1007\/s10792-025-03646-8.","journal-title":"Int Ophthalmol"},{"issue":"12","key":"738_CR28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/ph1712157435","volume":"17","author":"Y Ma","year":"2024","unstructured":"Ma Y, Tao Y, Yuan M, Sun X. Anti-Vascular endothelial growth factor combined with ocular steroid therapy for persistent diabetic macular edema: a systematic review and meta-analysis. Pharmaceuticals (Basel). 2024;17(12):1574. Published 2024 Nov 23. https:\/\/doi.org\/10.3390\/ph1712157435.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"738_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3760\/cma.j.cn115689-20240122-00346","volume":"51","author":"JL Yue","year":"2024","unstructured":"Yue JL, Long Y, Zhao MY. Effect of intravitreal injection of conbercept combined with panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy with macular edema. Chin J Practical Med. 2024;51(10):49\u201352. https:\/\/doi.org\/10.3760\/cma.j.cn115689-20240122-00346.","journal-title":"Chin J Practical Med"},{"issue":"02","key":"738_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3760\/cma.j.cn511434-20221222-00667","volume":"39","author":"JX Zhou","year":"2023","unstructured":"Zhou JX, Zhang JH. Observation on the efficacy of conbercept combined with subthreshold micropulsed laser photocoagulation in the treatment of diabetic macular edema. Chin J Ocular Fundus Dis. 2023;39(02):132\u20136. https:\/\/doi.org\/10.3760\/cma.j.cn511434-20221222-00667.","journal-title":"Chin J Ocular Fundus Dis"},{"issue":"32","key":"738_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.19347\/j.cnki.2096-1413.202232024","volume":"7","author":"G Duan","year":"2022","unstructured":"Duan G, Du B. Efficacy of conbercept combined with calcium dobesilate in treating diabetic macular edema and its effects on visual Acuity, CMT, TMV, and angiogenesis indicators. Clin Res Pract. 2022;7(32):86\u201390. https:\/\/doi.org\/10.19347\/j.cnki.2096-1413.202232024.","journal-title":"Clin Res Pract"},{"key":"738_CR32","doi-asserted-by":"publisher","unstructured":"Penha FM, Masud M, Khanani ZA et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous. 2024;10(1):5. Published 2024 Jan 17. https:\/\/doi.org\/10.1186\/s40942-024-00525-9.","DOI":"10.1186\/s40942-024-00525-9"},{"issue":"24","key":"738_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.19347\/j.cnki.2096-1413.202524046","volume":"10","author":"C Wu","year":"2025","unstructured":"Wu C, Pan XC, Zhang LM, et al. Research progress on traditional Chinese medicine compound combined with conbercept in the treatment of diabetic eye diseases. Clin Res Pract. 2025;10(24):187\u201390. https:\/\/doi.org\/10.19347\/j.cnki.2096-1413.202524046.","journal-title":"Clin Res Pract"},{"issue":"4","key":"738_CR34","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","volume":"143","author":"AM Khanani","year":"2025","unstructured":"Khanani AM, Campochiaro PA, Graff JM, et al. Continuous Ranibizumab via Port delivery system vs monthly Ranibizumab for treatment of diabetic macular edema: the pagoda randomized clinical trial. JAMA Ophthalmol. 2025;143(4):326\u201335. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.0006.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"738_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","volume":"257","author":"X Li","year":"2019","unstructured":"Li X, Dai H, Li X, et al. Efficacy and safety of Ranibizumab 0.5\u00a0mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefes Arch Clin Exp Ophthalmol. 2019;257(3):529\u201341. https:\/\/doi.org\/10.1007\/s00417-018-04213-x.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"738_CR36","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal Aflibercept for diabetic macular edema: 148-Week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376\u201385. https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.032.","journal-title":"Ophthalmology"},{"issue":"6","key":"738_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al. Faricimab Treat-and-Extend for diabetic macular edema: Two-Year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026.","journal-title":"Ophthalmology"},{"issue":"6","key":"738_CR38","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","volume":"28","author":"S Cai","year":"2017","unstructured":"Cai S, Bressler NM. Aflibercept, bevacizumab or Ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636\u201343. https:\/\/doi.org\/10.1097\/ICU.0000000000000424.","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"738_CR39","doi-asserted-by":"publisher","first-page":"22030","DOI":"10.1038\/s41598-020-78954-3","volume":"10","author":"YC Kim","year":"2020","unstructured":"Kim YC, Shin JP, Pak KY, et al. Two-year outcomes of the treat-and-extend regimen using Aflibercept for treating diabetic macular oedema. Sci Rep. 2020;10(1):22030. Published 2020 Dec 16. https:\/\/doi.org\/10.1038\/s41598-020-78954-3.","journal-title":"Sci Rep"},{"issue":"4","key":"738_CR40","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039.","journal-title":"Ophthalmology"},{"issue":"2","key":"738_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ophtha.2014.08.047","volume":"122","author":"MJ Elman","year":"2015","unstructured":"Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375\u201381. https:\/\/doi.org\/10.1016\/j.ophtha.2014.08.047.","journal-title":"Ophthalmology"},{"issue":"3","key":"738_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.18240\/ijo.2025.03.12","volume":"18","author":"W Wu","year":"2025","unstructured":"Wu W, Liu HD, Xiao X, et al. Renal dysfunction associated with clinical response to intravitreal conbercept therapy for diabetic macular edema. Int J Ophthalmol. 2025;18(3):454\u201361. Published 2025 Mar 18. https:\/\/doi.org\/10.18240\/ijo.2025.03.12.","journal-title":"Int J Ophthalmol"},{"key":"738_CR43","doi-asserted-by":"publisher","first-page":"e56741","DOI":"10.2196\/56741","volume":"10","author":"K Choi","year":"2024","unstructured":"Choi K, Park SJ, Yoon H, et al. Patient-Centered economic burden of diabetic macular edema: retrospective cohort study. JMIR Public Health Surveill. 2024;10:e56741. Published 2024 Oct 8. https:\/\/doi.org\/10.2196\/56741.","journal-title":"JMIR Public Health Surveill"},{"issue":"09","key":"738_CR44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13020-024-00964-4","volume":"31","author":"X Zhan","year":"2024","unstructured":"Zhan X, He Y, Shi YQ. Analysis of factors influencing the efficacy of intravitreal conbercept injection in patients with diabetic macular edema. China Contemp Med. 2024;31(09):92\u20135.","journal-title":"China Contemp Med"},{"issue":"1","key":"738_CR45","doi-asserted-by":"publisher","first-page":"22527","DOI":"10.1038\/s41598-022-26048-7","volume":"12","author":"EH Hong","year":"2022","unstructured":"Hong EH, Yeom H, Yu HS, et al. Genome-wide association study of the response of patients with diabetic macular edema to intravitreal Anti-VEGF injection. Sci Rep. 2022;12(1):22527. Published 2022 Dec 29. https:\/\/doi.org\/10.1038\/s41598-022-26048-7.","journal-title":"Sci Rep"},{"issue":"1","key":"738_CR46","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12886-020-01648-x","volume":"20","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Liang Y, Yan B, et al. Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography. BMC Ophthalmol. 2020;20(1):382. Published 2020 Sep 25. https:\/\/doi.org\/10.1186\/s12886-020-01648-x.","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"738_CR47","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.3390\/ijms24054676","volume":"24","author":"JY Yang","year":"2023","unstructured":"Yang JY, Goldberg D, Sobrin L. Interleukin-6 and macular edema: A review of outcomes with Inhibition. Int J Mol Sci. 2023;24(5):4676. Published 2023 Feb 28. https:\/\/doi.org\/10.3390\/ijms24054676.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"738_CR48","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/biology10121328","volume":"10","author":"L Huang","year":"2021","unstructured":"Huang L, Liang W, Zhou K, et al. Therapeutic effects of Fenofibrate Nano-Emulsion eye drops on retinal vascular leakage and neovascularization. Biology (Basel). 2021;10(12):1328. Published 2021 Dec 15. https:\/\/doi.org\/10.3390\/biology10121328.","journal-title":"Biology (Basel)"},{"issue":"8","key":"738_CR49","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14656566.2025.2496424","volume":"26","author":"LW Rowe","year":"2025","unstructured":"Rowe LW, Akotoye C, Harris A, Ciulla TA. Beyond the injection: delivery systems reshaping retinal disease management. Expert Opin Pharmacother. 2025;26(8):939\u201352. https:\/\/doi.org\/10.1080\/14656566.2025.2496424.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"738_CR50","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2337\/dc23-0993","volume":"47","author":"C Lam","year":"2024","unstructured":"Lam C, Wong YL, Tang Z, et al. Performance of artificial intelligence in detecting diabetic macular edema from fundus photography and optical coherence tomography images: A systematic review and Meta-analysis. Diabetes Care. 2024;47(2):304\u201319. https:\/\/doi.org\/10.2337\/dc23-0993.","journal-title":"Diabetes Care"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00738-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T07:29:47Z","timestamp":1765351787000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00738-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Article is updated to correct the error in funding section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}